Japan PMDA eCTD v4.0 Submissions: Process, Requirements and Global Differences

 In the second blog of our series on the evolution of eCTD v4.0, we take a closer look at what a typical eCTD v4.0 submission entails, how processes vary across regions, and key insights into the submission pathway for Japan’s PMDA.

A standard eCTD submission involves multiple stages—from selecting the appropriate regulatory pathway and submission type to preparing Modules 1 through 5, followed by compilation, quality control (QC), validation, and final submission. While the overarching framework remains consistent, each region has specific regulatory requirements. This makes it critical to collaborate with experienced partners to avoid unnecessary delays. In this blog, we outline a typical global submission process and highlight key differences between Japan, the EU, and the US.

eCTD v4.0 Submission Process: Japan PMDA and Global Differences

Although the core structure of eCTD submissions is harmonized, regional variations significantly impact execution:

  • Japan (PMDA):
    Utilizes a two-way submission approach:
    • Method 1: Submission of electronic study data or data specified under CTD notifications, depending on the submission type.
    • Method 2: Sequential submission using Type (b) followed by Type (c).
  • European Union (EMA):
    Follows procedure-based pathways, typically involving a four-step process.
    • Optional centralized procedure (CAP) or mutual recognition/decentralized procedures (MRP/DCP/NP).
    • Mandatory submissions depending on the chosen regulatory pathway.
  • United States (FDA):
    Operates through a simplified two-step process:
    • Initial sample submission and review/feedback.
    • Final submission of the original application.

What You Need to Know About PMDA’s eCTD v4.0 Adoption

Japan’s regulatory framework is largely electronic, though paper submissions may still be accepted in limited scenarios. The Pharmaceuticals and Medical Devices Agency (PMDA) oversees the review and approval process.

  • Electronic Submissions:
    PMDA strongly encourages—and for most new drug applications, requires—submissions in eCTD format.
  • eCTD Version Transition:
    While eCTD v3.2 remains the current standard, PMDA is actively transitioning to eCTD v4.0, which is presently available for voluntary submissions.
  • Gateway System:
    Submissions are typically routed through PMDA’s gateway system, with prior notification often required.
  • Consultation Services:
    PMDA provides consultation opportunities to guide applicants on clinical development, data expectations, and regulatory strategy—particularly valuable for complex or first-time submissions.
  • Language Requirements:
    Although certain documents (e.g., Clinical Study Reports) may be submitted in English, critical summaries must be in Japanese. Additionally, PMDA review queries and responses are generally conducted in Japanese.

Selecting the appropriate submission type for initial NDA filings is another critical step in Japan, as it directly influences submission timelines and regulatory strategy.

eCTD v4.0 Initial NDA Submission Types in Japan

  • jp_initial_a:
    Covers both study data and CTD-specified documents.
  • jp_initial_b:
    Includes only study data.
  • jp_initial_c:
    Includes only CTD-specified documents.
  • jp_other:
    Used only under exceptional circumstances when advised by the regulatory authority.

Transitioning to eCTD v4.0: What Happens to Legacy Submissions?

Following the mandatory adoption of eCTD v4.0 by regulatory authorities, submissions in outdated formats may face rejection, requests for resubmission, or extended review timelines.

However, eCTD v4.0 supports reuse of previously submitted content. The complexity of transitioning depends on several factors:

  • Original Format:
    Migrating from paper or legacy formats like NeeS is more complex than upgrading from eCTD v3.2.
  • Dossier Structure:
    Well-organized legacy dossiers are easier to map to the new format.
  • Tools and Expertise:
    Successful transitions require specialized software and experienced regulatory professionals.
  • Regulatory Guidance:
    Support varies by authority—some provide structured guidance, while others expect applicants to manage the transition independently.

Key Steps for Transitioning to eCTD v4.0

  • Gap Analysis:
    Assess differences between the existing dossier and eCTD v4.0 requirements.
  • Document Reorganization:
    Align content with the modular and more granular structure of eCTD v4.0.
  • Metadata Updates:
    Ensure compliance with updated specifications, including controlled vocabularies and unique identifiers (UUIDs).
  • XML Backbone Creation:
    Generate a single XML file that defines the dossier structure and links all documents—replacing the multiple XML files used in earlier versions.
  • Technical Validation:
    Validate the submission using compliant tools to ensure adherence to regulatory standards.
  • Final Submission:
    Submit the validated eCTD v4.0 dossier to the relevant health authority.

Given the complexity involved—especially when transitioning legacy submissions—partnering with the right regulatory experts is essential for seamless execution.

In our next blog, we will explore regional differences in controlled vocabularies, the importance of compliant tools, and best practices for successful submissions based on real-world experience across Japan, the US, and the EU.

Looking to streamline your regulatory submissions and accelerate timelines? Connect with Freyr to learn how we can support your eCTD v4.0 journey. https://japan.freyrsolutions.com/blogs/a-deep-dive-into-ectd-v4-0-submissions-japan-pmda-process-and-global-differences

Comments

Post a Comment

Popular posts from this blog

FDA GRAS Rule 2026: Key Changes, compliance & Industry Impact

Image
  FDA’s 2026 GRAS Proposal: A New Era of Food Ingredient Transparency By 2026, the U.S. Food and Drug Administration (FDA) is expected to publish a proposed regulation that would require all Generally Recognized as Safe (GRAS) determinations to be formally notified to the agency. If implemented, this rule would mark a major shift in food safety oversight—effectively ending the long-standing practice of self-affirmed GRAS determinations and ushering in a new era defined by transparency, accountability, and regulatory visibility. Understanding GRAS and Its Regulatory Role The GRAS (Generally Recognized as Safe) framework has been a foundational element of U.S. food ingredient regulation under the Federal Food, Drug, and Cosmetic Act. It allows substances to be used in food if they are generally recognized as safe by qualified experts, based on publicly available scientific evidence. Historically, companies have had two pathways: Submit a GRAS notification to the FDA ...
Read more

freya fusion vs Other RIMS: Comparison Guide for Japan

  Introduction: The Growing Demand for Smarter RIMS in Japan Every missed deadline in Japan’s pharma regulatory process can cost millions—and sometimes the market itself.  Rapid globalization, evolving PMDA guidelines, and the rising complexity of eCTD v4.0 compliance have placed enormous strain on regulatory affairs teams. Many Japanese companies still rely on  spreadsheets, fragmented systems, or legacy RIMS  platforms retrofitted with AI add-ons. These approaches struggle with speed, accuracy, and compliance readiness—especially when working across multiple regions. What’s needed is a next-generation regulatory information management system (RIMS) that can  streamline submissions, ensure compliance, and keep global teams aligned in  near  real-time . This is where  freya fusion , an  AI-First, unified RIMS platform , sets itself apart. In this blog, we’ll compare  freya fusion  with other leading RIMS solutions and analyze why it...
Read more

PFAS in Cosmetics: Why They Are Being Banned Globally

Image
  The Global Shift Away from PFAS in Cosmetics The beauty industry is undergoing a profound global transformation. Across the United States, multiple states are moving to ban PFAS (Per- and Polyfluoroalkyl Substances)—commonly known as “forever chemicals”—from cosmetic products. At the same time, Japan has taken a significant regulatory step by banning 138 PFAS under its Chemical Substances Control Law (CSCL), effective January 10, 2025. This regulation prohibits the manufacture, import, and use of these substances in cosmetics unless specific exemptions apply. As consumer demand shifts toward cleaner and safer beauty products, regulators are tightening controls on ingredients associated with long-term environmental and health risks. But what exactly is driving PFAS out of makeup bags worldwide? What Makes PFAS Problematic? PFAS represent a vast group of more than 10,000 synthetic chemicals valued for their resistance to water, oil, and heat. These properties have made them...
Read more